These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23231391)

  • 1. Parkinson's disease management. Part II- discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues.
    Reis J; Encarnação I; Gaspar A; Morales A; Milhazes N; Borges F
    Curr Top Med Chem; 2012; 12(20):2116-30. PubMed ID: 23231391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs.
    Helguera AM; Perez-Machado G; Cordeiro MN; Borges F
    Mini Rev Med Chem; 2012 Sep; 12(10):907-19. PubMed ID: 22420569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M; Sanz E
    Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
    Rojas RJ; Edmondson DE; Almos T; Scott R; Massari ME
    Bioorg Med Chem; 2015 Feb; 23(4):770-8. PubMed ID: 25600407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
    Tripathi AC; Upadhyay S; Paliwal S; Saraf SK
    Eur J Med Chem; 2018 Feb; 145():445-497. PubMed ID: 29335210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.
    Cruz-Monteagudo M; Borges F; Cordeiro MNDS; Helguera AM; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Perera-Sardina Y; Perez-Castillo Y
    Curr Neuropharmacol; 2017 Nov; 15(8):1117-1135. PubMed ID: 28093976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
    Prins LH; Petzer JP; Malan SF
    Eur J Med Chem; 2010 Oct; 45(10):4458-66. PubMed ID: 20674099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
    Legoabe LJ; Petzer A; Petzer JP
    Eur J Med Chem; 2012 Mar; 49():343-53. PubMed ID: 22309913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected chromone derivatives as inhibitors of monoamine oxidase.
    Legoabe LJ; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5480-4. PubMed ID: 22850212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
    Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
    Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Park HR; Kim J; Kim T; Jo S; Yeom M; Moon B; Choo IH; Lee J; Lim EJ; Park KD; Min SJ; Nam G; Keum G; Lee CJ; Choo H
    Bioorg Med Chem; 2013 Sep; 21(17):5480-7. PubMed ID: 23810676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
    Petzer JP; Petzer A
    Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B.
    Van der Walt MM; Terre'Blanche G; Petzer JP; Petzer A
    Eur J Med Chem; 2017 Jan; 125():1193-1199. PubMed ID: 27855360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
    Qhobosheane MA; Petzer A; Petzer JP; Legoabe LJ
    Bioorg Med Chem; 2018 Nov; 26(20):5531-5537. PubMed ID: 30279044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.